



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED SEPTEMBER 30, 2021.

Rs. In Lakhs

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 Months period ended		For the year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	118.41	200.61	897.96	319.02	1,040.82	1,347.83
	Other Income	50.28	455.52	227.72	505.80	480.65	775.37
	Total income	168.69	656.13	1,125.68	824.82	1,521.47	2,123.20
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	420.55	409.74	486.15	830.29	826.82	1,528.50
	d) Finance costs	14.99	15.29	25.32	30.28	47.25	81.54
	e) Depreciation and amortisation expense	103.43	103.43	107.46	206.86	213.95	434.62
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	602.49	884.01	701.93	1,486.50	1,196.66	2,517.04
	h) Other Expenses	125.51	92.95	94.25	218.46	180.68	356.99
	Total expenses	1,266.97	1,505.42	1,415.11	2,772.39	2,465.36	4,918.69
3	Profit before exceptional items & Tax (1-2)	(1,098.28)	(849.29)	(289.43)	(1,947.57)	(943.89)	(2,795.49)
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	(1,098.28)	(849.29)	(289.43)	(1,947.57)	(943.89)	(2,795.49)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	(99.46)	-	(346.18)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,098.28)	(849.29)	(189.97)	(1,947.57)	(597.71)	(2,263.21)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.79)	(11.79)	(11.35)	(23.58)	(22.70)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	3.96	-	7.93	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(11.79)	(11.79)	(7.39)	(23.58)	(14.77)	(30.67)
9	Total Comprehensive Income for the period (7+8)	(1,110.07)	(861.08)	(197.36)	(1,971.15)	(612.48)	(2,293.88)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity						35,200.64
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.86)	(0.67)	(0.15)	(1.53)	(0.47)	(1.78)
	b) Diluted	(0.86)	(0.67)	(0.15)	(1.53)	(0.47)	(1.78)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 Months period ended		For the year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	118.41	200.61	897.96	319.02	1,040.82	1,347.83
	Other Income	50.28	455.52	227.72	505.80	480.65	775.37
	Total income	168.69	656.13	1,125.68	824.82	1,521.47	2,123.20
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	514.35	505.53	571.74	1,019.88	985.56	1,852.75
	d) Finance costs	14.99	15.29	26.08	30.28	48.51	81.54
	e) Depreciation and amortisation expense	103.43	103.43	107.46	206.86	213.95	434.62
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	2,231.46	3,852.23	1,979.74	6,083.69	3,033.41	7,102.73
	h) Other Expenses	134.28	100.50	105.78	234.78	200.81	398.96
	Total expenses	2,998.51	4,576.98	2,790.80	7,575.49	4,482.24	9,870.60
3	Profit before exceptional items , Tax (1-2)	(2,829.82)	(3,920.85)	(1,665.12)	(6,750.67)	(2,960.77)	(7,747.40)
4	Exceptional Items- (Ref Note:7)	-	-	-	-	-	-
5	Profit before Tax (3-4)	(2,829.82)	(3,920.85)	(1,665.12)	(6,750.67)	(2,960.77)	(7,747.40)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	(99.46)	-	(346.18)	(532.28)
7	Net Profit/ (Loss) for the period/year(5-6)	(2,829.82)	(3,920.85)	(1,565.66)	(6,750.67)	(2,614.59)	(7,215.12)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(11.79)	(11.79)	(11.35)	(23.58)	(22.70)	(47.15)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	3.96	-	7.93	16.48
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(11.79)	(11.79)	(7.39)	(23.58)	(14.77)	(30.67)
9	Total Comprehensive Income for the period (7+ 8)	(2,841.61)	(3,932.64)	(1,573.05)	(6,774.25)	(2,629.36)	(7,245.79)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	-	-	5,835.74
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(2.22)	(3.08)	(1.23)	(5.30)	(2.05)	(5.67)
	b) Diluted	(2.22)	(3.08)	(1.23)	(5.30)	(2.05)	(5.67)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 25, 2021. The results for the quarter ended September 30, 2021 has been reviewed by our statutory auditors
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc
- 4) The COVID-19 did not have impact on the business and research operations in India. However, we are foreseeing certain delays in enrollment of ongoing phase 2 clinical studies conducted in our subsidiary, Suven Neurosciences, Inc USA.
- 5) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 6) During the year ended 31-03-2021 with the approval of members in EGM held on 20th March'2021, the board has issued 1,81,00,000 share warrants to promoter group on a preferential basis @ ₹ 81.57 per warrant and received amounting to ₹ 4,682.60 lakhs till 30.09.2021.
- 7) The other income includes Insurance claim amount received aggregating to Rs.371.58 lakhs.
- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : October 25, 2021



For SUVEN LIFE SCIENCES LTD

Venkat Jasti
VENKAT JASTI
Chairman & CEO
DIN: 00278028



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2021	31/03/2021	30/09/2021	31/03/2021
	UN AUDITED	AUDITED	UN AUDITED	AUDITED
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	1,660.85	1,774.48	1,660.85	1,774.48
(b) Capital Work-in-Progress	587.42	477.40	587.42	477.40
(c) Other Intangible Assets	23.77	13.60	23.77	13.60
(d) Right of use Assets	267.09	308.18	267.09	308.18
(e) Financial Assets				
I. Investments	34,666.97	29,502.55	-	-
(f) Other Non-current Assets	144.41	-	144.41	-
Total Non-Current assets	37,350.51	32,076.21	2,683.54	2,573.66
2 Current assets				
Inventories	15.00	14.15	15.00	14.15
(a) Financial Assets				
I. Investments	962.50	8.57	962.50	8.57
II. Trade Receivables	166.98	176.19	166.98	176.19
III. Cash and Cash equivalents	443.55	129.07	1,113.03	934.82
IV. Bank balances other than (III) above	36.81	3,730.12	36.81	3,730.12
V. Loans	-	4,144.87	-	4,144.87
(b) Current Tax asset (net)	559.70	534.78	559.70	534.78
(c) Other current assets	729.40	724.64	729.40	724.64
Total Current assets	2,913.94	9,462.39	3,583.42	10,268.14
TOTAL - ASSETS	40,264.45	41,538.60	6,266.96	12,841.80
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Warrant pending allotment	4,682.60	3,692.00	4,682.60	3,692.00
(c) Other Equity	33,229.49	35,200.64	(973.09)	5,835.74
Total Equity	39,184.91	40,165.46	4,982.33	10,800.56
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liabilities	198.62	232.60	198.62	232.60
II. Long-term Borrowings	-	39.25	-	39.25
(b) Provisions	172.87	172.87	172.87	172.87
(c) Other non current liabilities	-	5.56	-	5.56
(d) Deferred tax Liabilities (net)	-	-	-	-
Total non-current liabilities	371.49	450.28	371.49	450.28
Current liabilities				
(a) Financial Liabilities				
I. Lease Liabilities	111.47	110.11	111.47	110.11
II. Short-term Borrowings	89.18	94.40	89.18	94.40
III. Trade payables				
a) To Micro & Small Enterprises	5.68	19.61	5.68	19.61
b) Other than Micro & Small Enterprises	163.31	279.95	163.31	279.95
III. Other Financial Liabilities	203.07	268.15	408.16	936.25
(b) Other Current liabilities	57.00	72.30	57.00	72.30
(c) Provision Employee benefits	78.34	78.34	78.34	78.34
Total - Current liabilities	708.05	922.86	913.14	1,590.96
Total Liabilities	1,079.54	1,373.14	1,284.63	2,041.24
TOTAL - EQUITY AND LIABILITIES	40,264.45	41,538.60	6,266.96	12,841.80

For Suven Life Sciences Ltd

Place : Hyderabad

Date: October 25, 2021



Venkat Jasti

Venkat Jasti
Chairman & CEO

SUVEN LIFE SCIENCES LTD

Unaudited Standalone Cash flow statement

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2021	For the half year ended September 30, 2020
A. Cash flow from operating activities		
Profit/(Loss) before tax	(1,947.57)	(943.89)
Adjustments :		
Depreciation and amortisation expense	165.77	172.86
Interest Income	(112.16)	(450.81)
Finance Cost	30.28	47.25
Gain on Insurance receipt	(371.58)	-
Unrealised/sale of Gain on Current Investment	(15.45)	(3.66)
Operating profit before working capital changes	(2,250.71)	(1,178.26)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	9.22	(59.22)
Inventories	(0.85)	(15.04)
Other non current assets	(103.32)	29.90
Other current financial assets	-	0.10
Other current assets	366.81	(261.21)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(130.57)	(275.80)
Long term provisions	-	17.21
Other non-current liabilities	(5.56)	(14.53)
Short term provision	(23.58)	20.59
Other financial liabilities	(73.61)	234.41
Other current liabilities	(15.30)	24.83
Cash generated from operating activities	(2,227.47)	(1,477.03)
Income taxes paid (net of refunds)	24.93	38.52
Net Cash flows from operating activities	(2,252.40)	(1,515.55)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(172.33)	(271.20)
Current financial assets	4,144.87	3,623.43
Interest received	112.16	450.81
Changes in Investments	(5,164.42)	(1,650.06)
Sale/(purchase) of mutual funds	(938.47)	(499.98)
Bank balances not considered as cash and cash equivalents	1.31	0.23
Net cash flow from /(used in) investing activities	(2,016.88)	1,653.23
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	(44.47)	(36.81)
Proceeds from share warrants	4,682.60	-
Changes In Lease Liability	(32.62)	(26.31)
Finance Cost	(21.75)	(47.25)
Net cash flow from /(used In) financing activities	4,583.76	(110.37)
Net increase/(decrease) in cash and cash equivalents	314.48	27.31
Cash and cash equivalents as at the beginning of the year	129.07	70.76
Cash and cash equivalents at the end of the year	443.55	98.07
Cash and cash equivalents	443.55	98.07
Balances per statement of cash flows	443.55	98.07

For Suven Life Sciences Ltd



Yenkat Jasti

Yenkat Jasti
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : October 25, 2021

SUVEN LIFE SCIENCES LTD

Unaudited Consolidated Cash flow statement

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2021	For the half year ended September 30, 2020
A. Cash flow from operating activities		
Profit/(Loss) before tax	(6,750.67)	(2,960.77)
Adjustments :		
Depreciation and amortisation expense	165.77	172.86
Interest Income	(112.16)	(450.81)
Finance Cost	30.28	48.51
Gain on Insurance receipt	(371.58)	-
Unrealised/sale of Gain on Current Investment	(15.45)	(3.66)
Operating profit before working capital changes	(7,053.81)	(3,193.88)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	9.22	(59.22)
Inventories	(0.85)	(15.04)
Other non current assets	(103.32)	29.90
Other current financial assets	-	2.15
Other current assets	366.81	(261.21)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(130.57)	(275.79)
Long term provisions	-	17.21
Other non-current liabilities	(5.56)	(14.53)
Short term provision	(23.58)	20.59
Other financial liabilities	(536.61)	(734.21)
Other current liabilities	(15.30)	24.83
Cash generated from operating activities	(7,493.57)	(4,459.21)
Income taxes paid (net of refunds)	24.93	38.52
Net Cash flows from operating activities	(7,518.50)	(4,497.73)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(172.33)	(271.20)
Loan repayment received	4,144.87	3,623.43
Interest received	112.16	450.81
Sale/(purchase) of mutual funds	(938.47)	(499.98)
Foreign currency translation reserve	(34.59)	3.62
Bank balances not considered as cash and cash equivalents	1.31	0.23
Net cash flow from /(used in) investing activities	3,112.95	3,306.91
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	(44.47)	(36.81)
Proceeds from share warrants	4,682.60	-
Changes In Lease Liability	(32.62)	(26.31)
Finance Cost	(21.75)	(48.51)
Net cash flow from /(used In) financing activities	4,583.76	(111.63)
Net increase/(decrease) in cash and cash equivalents	178.21	(1,302.45)
Cash and cash equivalents as at the beginning of the year (Refer Note 5)	934.82	1,467.57
Cash and cash equivalents at the end of the year	1,113.03	165.12
Cash and cash equivalents (Refer Note 5(d)(i))	1,113.03	165.12
Balances per statement of cash flows	1,113.03	165.12

For Suven Life Sciences Ltd



Venkat Jasti
Venkat Jasti
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : October 25, 2021